安徽医科大学学报Issue(5)：640-644,5.
ERCC1基因检测指导晚期食管癌个体化治疗的临床研究
Clinical research of individualized therapy in advanced esophageal cancer guiding by detection of ERCC1 C8092A
摘要
Abstract
Objective To explore the role and clinical values of detection of excision repair cross-complementing 1 (ERCC1) C8092A polymorphisms in individualized therapy of advanced esophageal cancer patients. Methods 114 advanced esophageal cancer patients were enrolled. Patients were randomly assigned to either the standard treatment group or the individualized treatment group. Patients in the standard treatment group received Paclitaxel plus cispla-tin. In the individualized treatment group,the ERCC1 C8092A polymorphisms were detected after DNA PCR ampli-fications,which extracted from peripheral blood karyocytes before the chemotherapies used. Patients with the AA or AC genotype of ERCC1 C8092A received Paclitaxel plus cisplatin,and those with CC genotype received Paclitaxel plus fluorouracil. The primary endpoints were response rate. The sencondary endpoints were toxicity of chemothera-py,progression freesurvival and overall survival. Differences between the groups were statistically analyzed by chi square test. Survival Differences were analyzed by Kaplan Meiersurvival curves. The survival rate was analyzed by Log Rank test. Results Response rate in the standard treatment group was 31. 6% . In the individualized treatment group was 53. 9% . There was statistically significant difference between two groups (P < 0. 05). The rates of gradeⅢ ~ Ⅳ nausea and vomitting (32. 9% ),anemia (11. 8% ) were significantly lower in individualized treatment group than in standard treatment group(68. 4% ,28. 9% ). There was statistically significant difference between the two groups (P < 0. 001,P = 0. 001). The media progression free survival time and overall survival time were signifi-cantly better in individualized treatment group than in standard treatment group (P = 0. 004,P = 0. 007). Conclu-sion The RR,toxicity of chemotherapy,PFS and OS are significantly better in individualized treatment group than in standard treatment group. Detection of ERCC1 gene polymorphism might be performed for advanced esophageal cancer patients to be better individualized,which is worthy of further study.关键词
食管癌/个体化治疗/核苷酸切除修复交叉互补组/顺铂Key words
esophageal cancer/individualized therapy/excision repair cross-complementing/cisplatin分类
医药卫生引用本文复制引用
姚艺玮,何义富,季楚舒,韩兴华,胡冰..ERCC1基因检测指导晚期食管癌个体化治疗的临床研究[J].安徽医科大学学报,2015,(5):640-644,5.基金项目
安徽省卫生厅医学科研课题(编号:2010B001) （编号:2010B001）
